ORIGINAL PAPER



Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM

Euibeom Shin¹ · Yifan Yu¹ · Robert R. Bies¹ · Murali Ramanathan¹

Received: 29 March 2024 / Accepted: 16 April 2024 / Published online: 24 April 2024 © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024

Abstract

To assess ChatGPT 4.0 (ChatGPT) and Gemini Ultra 1.0 (Gemini) large language models on NONMEM coding tasks relevant to pharmacometrics and clinical pharmacology. ChatGPT and Gemini were assessed on tasks mimicking real-world applications of NONMEM. The tasks ranged from providing a curriculum for learning NONMEM, an overview of NONMEM code structure to generating code. Prompts in lay language to elicit NONMEM code for a linear pharmacokinetic (PK) model with oral administration and a more complex model with two parallel first-order absorption mechanisms were investigated. Reproducibility and the impact of "temperature" hyperparameter settings were assessed. The code was reviewed by two NONMEM experts. ChatGPT and Gemini provided NONMEM curriculum structures combining foundational knowledge with advanced concepts (e.g., covariate modeling and Bayesian approaches) and practical skills including NONMEM code structure and syntax. ChatGPT provided an informative summary of the NONMEM control stream structure and outlined the key NONMEM control stream from the lay language prompts for the two coding tasks. The control streams contained focal structural and syntax errors that required revision before they could be executed without errors and warnings. The code output from ChatGPT and Gemini was not reproducible, and varying the temperature hyperparameter did not reduce the errors and omissions substantively. Large language models may be useful in pharmacometrics for efficiently generating an initial coding template for modeling projects. However, the output can contain errors and omissions that require correction.

Keywords Pharmacometrics \cdot ChatGPT \cdot Pharmacokinetics \cdot Drug Development \cdot Artificial intelligence \cdot Generative AI \cdot Modeling \cdot Nonlinear mixed effects \cdot NONMEM

Introduction

Large language models (LLM), as exemplified by ChatGPT from OpenAI, Gemini from Google, Llama from Meta, and Claude from Anthropic [1–5], are widely viewed as an important advancement in the field of artificial intelligence (AI) as they are capable of emulating human-like text generation and comprehension [6]. Usage of LLM has increased rapidly since they are versatile, user-friendly, and can assist with diverse tasks, e.g., engaging in casual conversations and document editing to solving complex, problemoriented queries [7]. LLM can generate software code and

Murali Ramanathan Murali@Buffalo.Edu language-based text with a degree of sophistication that suggests potential utility in pharmacometrics [8].

Pharmacometrics approaches enable analysis of the time courses and variability of drug concentrations [9], and are leveraged to inform dosage recommendations and therapeutic strategies [10]. NONMEM is a software package for implementing nonlinear mixed effects regression methods that is widely used by pharmacometricians [11]. NONMEM employs the NONMEM Translator (NM-TRAN) language for coding, which we refer to hereinafter simply as NON-MEM code. NONMEM-coded nonlinear mixed effects regression analyses of compartmental pharmacokinetic models are commonly summarized in the new drug applications that are submitted to regulatory agencies such as the Food and Drug Administration and European Medicines Agency to support marketing approval for innovator products [12].

ChatGPT, Gemini, and other LLM have already proven useful for generating code in commonly used programming

¹ Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14214-8033, USA

languages such as C + +, Python, and R. Thus, integration of ChatGPT into a NONMEM workflow presents an emerging opportunity to enhance the productivity of coding tasks for pharmacometrics modeling [13, 14]. In addition to coding, ChatGPT could potentially streamline aspects of modeling documentation and be used for learning NONMEM and pharmacometrics.

The key research aim was to assess the capabilities and limitations of ChatGPT 4.0 and Gemini Ultra 1.0 in interpreting lay language prompts for pharmacometric modeling tasks designed to elicit corresponding NONMEM code. The tasks were selected to mirror the practical applications of NONMEM in pharmacometrics and clinical pharmacology settings [10] and covered a range of activities, from providing a curriculum for learning and understanding NONMEM code structure to developing code for different pharmacokinetic (PK) models. The NONMEM tasks included coding for a linear PK model with oral administration and a more complex one-compartment model with two parallel firstorder absorption mechanisms.

Methods

ChatGPT & Gemini methods

The default version of ChatGPT 4.0 [15] and Gemini Ultra 1.0 [2] were run at chat.openai.com and gemini.google. com, respectively, on a MacBook Air computer running macOS Ventura 13.5.1. Screenshots from individual runs were saved.

ChatGPT 4.0 and Gemini Ultra 1.0 are hereinafter referred to as ChatGPT and Gemini, respectively.

Case studies

Two types of prompts were provided to ChatGPT and Gemini to generate output. The first related to teaching elements of NONMEM (Case Studies 1 and 2) and the second related to generating NONMEM code for a specific population PK example (Case Studies 3A and 3B).

We assessed ChatGPT and Gemini's capability to comprehend and instruct on pharmacokinetic/pharmacodynamic (PK/PD) modeling with NONMEM, focusing on a one-compartment model analysis.

A structured sequence of prompts was designed to engage the LLM in a step-by-step process, beginning with an explanation of NONMEM principles and culminating in a practical demonstration of NONMEM code. For convenience of presentation, Case Study 1 was a curricular framework for learning NONMEM in context, Case Study 2 was a request for a specific explanation of NONMEM code, whereas Case Study 3A and Case Study 3B evaluated the ability of ChatGPT and Gemini to generate NONMEM code for specific pharmacokinetic models. The following prompts were entered for the four Case Studies.

Case study 1

If you were a teacher, what topics related to NONMEM would you teach students?

Case study 2

You are an expert NONMEM code writer for population PKPD in the pharmaceutical industry. You are always accurate and precise when formulating NONMEM code. Please describe the structure of NONMEM code using a basic example.

Case study 3A

Can you provide the NONMEM code for a linear PK model with oral administration?

Case study 3B

Provide NONMEM code for a one-compartment model with two parallel absorptions and linear elimination.

Case 1, Case 2, and Case 3A were run together in a single chat session, and Case 3B was running on a separate chat.

The prompt engineering strategy included persona crafting to embody an expert NONMEM coder, role assignment to align with instructional tasks, and sequential prompting to maintain context throughout the interaction.

The code generated was reviewed carefully for errors and omissions by two individuals (authors: YY, RRB) with NONMEM expertise.

Evaluation of reproducibility

Three replicate experiments were conducted with ChatGPT and Gemini for Case Study 3A and Case Study 3B. The prompts described in the preceding section were re-used verbatim.

Evaluating the effect of varying the "Temperature" hyperparameter

The "temperature" hyperparameter (T) of ChatGPT controls the balance between randomness and determinism in the results. Experiments with T values of 0.1, 0.33 and 1 were conducted for Case Study 3A and Case Study 3B.

These runs were conducted using OpenAI Playground, Model: GPT-4 Turbo preview (https://platform.openai. com/docs/models), which allows the temperature parameter to be set by the user. The other parameters were fixed to Maximumlength = 4095, TopP = 1, Frequencypenalty = 0, and Presencepenalty = 0.

Results

Case study 1: Curricular framework for teaching NONMEM

Case study 1

If you were a teacher, what topics related to NONMEM would you teach students?

Figure 1 compares NONMEM related topics provided by ChatGPT and Gemini results.

ChatGPT

The ChatGPT's response reflects its utility for structuring a NONMEM curriculum that combines foundational knowledge with advanced concepts and practical skills.

The topic list proposed by ChatGPT starts with pharmacometrics principles to establish a foundation before progressing to advanced aspects. It provided technical requirements for NONMEM software installation, setup, and data management.

The response also included a detailed exploration of NONMEM code structure and syntax to equip learners with coding skills. Advanced topics, like covariate modeling and Bayesian approaches were integrated and showcasing the curriculum's depth. Practical applications, including simulations and predictive model checks, were also covered.

Moreover, the topic list addressed regulatory considerations and documentation practices in PKPD modeling, aligning with industry standards. It also keeps pace with current trends and future directions in pharmacometrics, ensuring contemporary relevance.

Gemini

The overall outline of Gemini's syllabus resembled the ChatGPT's in that it listed the introduction to PKPD, the fundamental structure of the NONMEM, basic structural PK models, and intermediate/advanced topics.

Gemini suggested learning foundational concepts of pharmacometrics and NONMEM including inter-individual variability and covariate modeling and then covering topics related to the fundamentals of more intermediate/advanced population agnostic pharmacokinetic models such as Michaelis–Menten elimination and target-mediated drug disposition. However, inter-individual variability, a basic topic was included in the intermediate section. It further provided the model evaluation and diagnostic methods, including the visual predictive checks and bootstrap techniques. Gemini included some basic goodness of fit approaches under an advanced topics heading. Gemini ended with a similar emphasis as Chat-GPT, by analyzing real-world PKPD datasets.

Case study 2. Explanation of NONMEM code

Case study 2

You are an expert NONMEM code writer for population PKPD in the pharmaceutical industry. You are always accurate and precise when formulating NONMEM code. Please describe the structure of NONMEM code using a basic example.

Figure 2 summarizes the ChatGPT and Gemini results for Case Study 2.

ChatGPT

ChatGPT effectively communicated complex pharmacometrics concepts and provided an informative summary of NONMEM code structure.

The key components of NONMEM code, starting with the Problem Statement (\$*PROB*), which functions as the model's title or description, were provided. This was followed by Input Data Specification (\$*DATA*) for defining the dataset file and format, and Input Variable Definitions (\$*INPUT*), detailing essential variables such as *ID*, *TIME*, *DV*, and *AMT*.

The Model Specification (\$*PRED* or \$*MODEL*) section containing model equations, Estimation Method (\$*ESTIMATION*) for the selecting parameter estimation algorithm, and Output Specification (\$*TABLE*) for defining the output format were also described. The response also included sections such as \$*COV* for specifying the covariance matrix and \$*THETA* for providing starting parameter estimates and bounds.

ChatGPT also provided a basic pharmacokinetic model as an example (Fig. 2), clarifying key parameters such as clearance (CL), volume of distribution (V), and absorption rate constant (KA).

Figure 2 also summarizes the errors in the model components. First, ChatGPT incorrectly used \$*PARAM* to define initial parameter estimates instead of \$*THETA*, which is the appropriate block for defining initial estimates for fixed effects parameters. Secondly, ChatGPT provided an incorrect example for \$*PRED*. ChatGPT used \$*PRED* to code a one compartment model with first order absorption, without using *PREDPP*, a library of pre-written modeling in NONMEM. However, it incorrectly stated that \$*PRED* is for "predictive model", and the equations presented by ChatGPT within \$*PRED* were incorrect. For the one-compartment, first-order absorption Fig. 1 Topics related to NON-MEM identified by ChatGPT and Gemini

ChatGPT

ChatGPT As a teacher focusing on NONMEM, I would aim to cover a comprehensive range of topics that not only introduce the basics of NONMEM but also delive into advanced applications relevant to pharmacokinetics/pharmacodynamics (PKPD) modeling. Here's an outline of the topics I would include in the curriculum:

1. Introduction to Pharmacometrics and NONMEM:

- Overview of pharmacometrics in drug development.
 Introduction to NONMEM and its role in PKPD modeling.
- Basic principles of nonlinear mixed-effects modeling.
- 2. Getting Started with NONMEM:
 - Installation and setup of NONMEM.
 - Understanding the NONMEM environment and interface.
 Basic structure of NONMEM datasets and code.
- 3. Data Preparation and Management:
 - Data requirements for PKPD modeling.
 - Techniques for data cleaning and preparation.
- Best practices for dataset organization and management.
 Basic PKPD Modeling Concepts:
 - Fundamentals of pharmacokinetics (absorption, distribution, metabolism, excretion).
 - Basic pharmacodynamic principles and models.
 - * Introduction to compartmental and non-compartmental analysis.
- 5. NONMEM Code Structure and Syntax:
 - Detailed walkthrough of NONMEM code components (\$PROB, \$DATA, \$INPUT, etc.).
 - Writing and interpreting basic PK models in NONMEM.
- Debugging and troubleshooting common errors in NONMEM code.

6. Parameter Estimation and Model Evaluation:

- Methods for parameter estimation in NONMEM (e.g., FOCE, FOCEI).
- Goodness-of-fit evaluations and diagnostic plots.
- Model selection criteria and techniques.
- 7. Advanced Modeling Techniques:
 - Covariate modeling and its importance in PKPD analysis.
 - Population PKPD modeling and its applications.
 Introduction to Bayesian approaches in NONMEM.
- 8. Simulation and Predictions:
 - Conducting simulations in NONMEM for different scenarios.
 - Predictive model checks and their interpretation.
 Use of simulations for dose optimization and clinical trial design.
- 9. Regulatory Considerations and Reporting:
 - Understanding regulatory requirements for PKPD modeling.
 - Best practices for model documentation and reporting.
 - Preparing materials for regulatory submissions.
- 10. Current Trends and Research in NONMEM:
 - Discussion on the latest development: VONMEM and pharmacometrics.
 Exploring real-world applications and case studies.
 - Future directions in the field of pharmacometrics.

Throughout the course, practical sessions and workshops using real-life examples an datasets would be crucial for hands-on learning. Additionally, I would encourage discussions on the ethical and practical implications of PKPD modeling in drug development and clinical decision-making.

Gemini

- P If you were a teacher, what topics related to NONMEM would you teach students?
- If I were a NONMEM teacher, I would structure my teaching into a progressive curriculum to help students develop a strong foundation and then layer on more complex concepts. Here's the breakdown:

Foundational Concepts

1. Introduction to Pharmacokinetics (PK) and Pharmacodynamics (PD):

- Basic PK concepts: Absorption, Distribution, Metabolism, Excretion (ADMF).
- PK parameters: Clearance, volume of distribution, half-life, etc.
- · Pharmacodynamic concepts: dose-response relationships, Emax models

2. NONMEM Fundamentals:

- Purpose of NONMEM in population PKPD modeling.
- Structure of NONMEM control streams: \$PROBLEM, \$INPUT, \$DATA, \$MODEL,
- Linear vs. non-linear mixed-effects modeling.

3. Basic Structural PK Models:

- · One-compartment and two-compartment models with different routes of
- administration (IV bolus, IV infusion, oral absorption).
- Incorporating lag-time and transit compartments for oral absorption.

Intermediate Concepts

- 4. Inter-Individual Variability (IIV):
- Understanding random effects: ETAs.
- · Implementing IIV on PK parameters using exponential models
- Covariance between random effects (OMEGA block).

5. Covariate Modeling:

- · Importance of covariates: Explaining variability based on patient
- characteristics (age, weight, sex, etc.).
- Linear, power, and exponential covariate relationships.
- Methods for covariate selection and inclusion

6. Residual Error Models:

- Types of error models: additive, proportional, combined.
- Diagnosing model fit using residual plots.

Advanced Topics

7. Non-linear Kinetics:

Michaelis-Menten elimination.

Target-mediated drug disposition (TMDD).

8. PKPD Modeling:

• Linking PK models to pharmacodynamic effects.

9. Model Evaluation and Diagnostics:

- 9. Model Evaluation and Diagnostics:
- · Goodness-of-fit plots (observed vs. predicted, residual plots)
- Visual Predictive Checks (VPCs).
 Bootstrap techniques.

10. Estimation Methods:

- · Understanding different methods (FO, FOCE, Laplace) and their trade-offs.
- Simulation methods like Importance Sampling.

Practical Skills Development

- Data Preparation: Formatting data for NONMEM.
- Software: Hands-on experience with NONMEM, PsN (Perl-speaks-NONMEM), Pirana, and visualization tools (R, etc.)
- Model Building Strategies: Iterative process, problem-solving.
- Interpretation and Communication of Results: Translating findings to clinical stakeholders.

Beyond the Classroom

- Case Studies: Analyzing real-world PKPD datasets.
- Literature Review: Keeping up-to-date with advances in the field.
- NONMEM User Community: Participation in forums for troubleshooting and
- further learning.

Let me know if you'd like a deeper dive into a particular topic or would want examples of how I might teach one of these!

model, the Bateman function should be used to calculate concentration in the central compartment:

$$Y = AMT * KA/(V * KA - CL/V)$$

* (EXP(-CL/V * TIME) - EXP(-KA * TIME))

Moreover, In the final part of ChatGPT's answer, it mistakenly identified \$*COV* and \$*THETA* as "Control Termination".

Additionally, ChatGPT did not provide any introduction for \$*PK* or \$*SUBROUTINE* which are important code components for modeling the values of basic and additional PK parameters when using *PREDPP*. **Fig. 2** The ChatGPT prompt and the resulting output from ChatGPT for Case Study 2. The errors and omissions in the code are highlighted in rectangles and described in the gold boxes

ChatGPT

You You are an expert NONMEM code writer for population PKPD in the pharmaceutical industry. You are always accurate and precise when formulating NONMEM code. Please describe the structure of NONMEM code using a basic example.

ChatGPT

- NONMEM (Nonlinear Mixed Effects Modeling) is a software used in pharmacokinetics and pharmacodynamics (PKPD) for analyzing population data. Writing NONMEM code involves several key components, each serving a specific purpose in the modeling process. Here's balac structure of a trucical NONMEM code with a simple example.
- 1. Problem Statement (*\$PROB '): This section describes the problem or model being

	analyzed. It's essentially a title or brief description.				
	plaintext D Copy code				
	\$PROB Basic PK model for Drug X				
2.	Input Data Specification (* \$DATA *): Specifies the dataset file to be used, including its format.				
	plaintext 🖸 Copy code				
	\$DATA dataset.csv IGNORE=C				
	SUATA Gataset.csv lunure=t				
3.	Input Variable Definitions (* \$INPUT '): Defines the variables in the dataset.				
	plaintext 🗅 Copy code				
	\$INPUT ID TIME DV AMT				
4.	Parameter Definitions (`\$PARAM`): Define^ 'nitial estimates of the parameters of the				
	model.				
	plaintext 🗅 Copy code				
	SPARAM CL=1.0 V=10 KA=0.5 \$PARAM should be \$THETA				
5.	Model Specification ('\$PRED' or '\$MODEL'): Describes the mathematical model.				
	*\$PRED ' is for the predictive model, while *\$MODEL ' defines the structural model				
	components like compartments.				
	plaintext 🗋 Copy code				
	SPRED Wrong equations				
	F = KA*AMT Incorrect description of model				
	G = EXP(-KA*TIME)				
	$Y = F^{G}/(CL/V)$				
0					
6.	Estimation Method (`\$ESTIMATION`): Specifies the method and options for parameter				
6.					
6.	Estimation Method (' \$ESTIMATION'): Specifies the method and options for parameter estimation.				
6.	Estimation Method (SESTIMATION): Specifies the method and options for parameter estimation.				
	Estimation Method ('\$ESTIMATION'): Specifies the method and options for parameter estimation. plantex Copy code \$EST METHOD=1 INTER Output Specification ('\$TABLE'): Defines what output should be generated and its				
	Estimation Method (' \$ESTIMATION'): Specifies the method and options for parameter estimation. plantext Copy code \$EST METHOD=1_INTER Output Specification ('\$TABLE'): Defines what output should be generated and its format.				
	Estimation Method ('ESTIMATION '): Specifies the method and options for parameter estimation. plantex Corpy code SEST METHOD=1 INTER Output Specification ('STABLE '): Defines what output should be generated and its format. plantex Copy code				
	Estimation Method (' \$ESTIMATION'): Specifies the method and options for parameter estimation. plantext Copy code \$EST METHOD=1_INTER Output Specification ('\$TABLE'): Defines what output should be generated and its format.				
7.	Estimation Method ('\$ESTIMATION '): Specifies the method and options for parameter estimation. plaintex Corpy code \$EST METHOD=1 INTER Output Specification ('\$TABLE '): Defines what output should be generated and its format. plaintext. Control Termination ['\$COV', '\$THETA', etc.): Additional sections for specifying				
7.	Estimation Method (' \$ESTIMATION'): Specifies the method and options for parameter estimation.				
7.	Estimation Method (' \$ESTIMATION'): Specifies the method and options for parameter estimation.				
7.	Estimation Method ('\$ESTIMATION '): Specifies the method and options for parameter estimation. plantex Corp code SEST METHOD=1 INTER Output Specification ('\$TABLE '): Defines what output should be generated and its format. plantex Control Termination ('\$COV', '\$THETA', etc.): Additional sections for specifying covariance, theta bounds, and other controls. Control Termination Control Section C' is clearance, 'V' is volume of distribution, and 'KA' is the absorption rate constant. The model predicts				
8.	Estimation Method (\$ESTIMATION '): Specifies the method and options for parameter estimation. plaintex © Copy code SEST METHOD=1 INTER Output Specification (\$TABLE '): Defines what output should be generated and its format. plaintex © Copy code STABLE ID TIME PRED DV Control Termination (' \$COV', 'STHETA', etc.): Additional sections for specifying covariance, theta bounds, and other controls. This example outlines a basic pharmacokin-uc model where 'CL' is clearance, 'V' is oulume of distribution, and 'KA' is the absorption rate constant. The model predicts the concentration ('Y') at various times ('TIME') after dosing ('AMT'). In real-world				
7.	Estimation Method (`\$ESTIMATION`): Specifies the method and options for parameter estimation. plantax © Copy code \$EST_METHOD=1_INTER Output Specification (`\$TABLE`): Defines what output should be generated and its format. plantax © Copy code \$TABLE ID_TIME_PRED_DV Control Termination (`\$COV`, `\$THETA`, etc.): Additional sections for specifying covariance, theta bounds, and other controls. Control Termination This example outlines a basic pharmackkin-uc model where 'CL` is clearance, 'V` is volume of distribution, and 'KA` is the absorption rate constant. The model predicts volume of distribution ('Y) at various times ('TIME') after dosing ('ATT'). In real-world applications, NONMEM code can become quite complex, incorporating advanced				
7.	Estimation Method (\$ESTIMATION '): Specifies the method and options for parameter estimation. plaintex © Copy code SEST METHOD=1 INTER Output Specification (\$TABLE '): Defines what output should be generated and its format. plaintex © Copy code STABLE ID TIME PRED DV Control Termination (' \$COV', 'STHETA', etc.): Additional sections for specifying covariance, theta bounds, and other controls. This example outlines a basic pharmacokin-uc model where 'CL' is clearance, 'V' is oulume of distribution, and 'KA' is the absorption rate constant. The model predicts the concentration ('Y') at various times ('TIME') after dosing ('AMT'). In real-world				
7.	Estimation Method (`\$ESTIMATION`): Specifies the method and options for parameter estimation. plantax © Copy code \$EST_METHOD=1_INTER Output Specification (`\$TABLE`): Defines what output should be generated and its format. plantax © Copy code \$TABLE ID_TIME_PRED_DV Control Termination (`\$COV`, `\$THETA`, etc.): Additional sections for specifying covariance, theta bounds, and other controls. Control Termination This example outlines a basic pharmackkin-uc model where 'CL` is clearance, 'V` is volume of distribution, and 'KA` is the absorption rate constant. The model predicts volume of distribution ('Y) at various times ('TIME') after dosing ('ATT'). In real-world applications, NONMEM code can become quite complex, incorporating advanced				
7.	Estimation Method (`\$ESTIMATION`): Specifies the method and options for parameter estimation. plantax © Copy code \$EST_METHOD=1_INTER Output Specification (`\$TABLE`): Defines what output should be generated and its format. plantax © Copy code \$TABLE ID_TIME_PRED_DV Control Termination (`\$COV`, `\$THETA`, etc.): Additional sections for specifying covariance, theta bounds, and other controls. Control Termination This example outlines a basic pharmackkin-uc model where 'CL` is clearance, 'V` is volume of distribution, and 'KA` is the absorption rate constant. The model predicts volume of distribution ('Y) at various times ('TIME') after dosing ('ATT'). In real-world applications, NONMEM code can become quite complex, incorporating advanced				
7.	Estimation Method (`\$ESTIMATION`): Specifies the method and options for parameter estimation. plantax © Copy code \$EST_METHOD=1_INTER Output Specification (`\$TABLE`): Defines what output should be generated and its format. plantax © Copy code \$TABLE ID_TIME_PRED_DV Control Termination (`\$COV`, `\$THETA`, etc.): Additional sections for specifying covariance, theta bounds, and other controls. Control Termination This example outlines a basic pharmackkin-uc model where 'CL` is clearance, 'V` is volume of distribution, and 'KA` is the absorption rate constant. The model predicts volume of distribution ('Y) at various times ('TIME') after dosing ('ATT'). In real-world applications, NONMEM code can become quite complex, incorporating advanced				
7.	Estimation Method (`\$ESTIMATION`): Specifies the method and options for parameter estimation. plantax © Copy code \$EST_METHOD=1_INTER Output Specification (`\$TABLE`): Defines what output should be generated and its format. plantax © Copy code \$TABLE ID_TIME_PRED_DV Control Termination (`\$COV`, `\$THETA`, etc.): Additional sections for specifying covariance, theta bounds, and other controls. Control Termination This example outlines a basic pharmackkin-uc model where 'CL` is clearance, 'V` is volume of distribution, and 'KA` is the absorption rate constant. The model predicts volume of distribution ('Y) at various times ('TIME') after dosing ('ATT'). In real-world applications, NONMEM code can become quite complex, incorporating advanced				

Gemini

- You are an expert NONMEM code writer for population PKPD in the pharmaceutical industry. You are always accurate and precise when formulating NONMEM code. Please describe the structure of NONMEM code using a basic example.
- Absolutely! Let's break down the structure of NONMEM code using a simple onecompartment pharmacokinetic (PK) model example.

Core Structure of NONMEM Code

A NONMEM control stream (the file containing your code) typically includes the following sections:

- 1. **\$PROBLEM:** A short title or description of your analysis.
- \$INPUT: Specifies which columns in your data file contain important information (subject ID, time, dose, observations, covariates, etc.).
- 3. **\$DATA:** The path to your dataset file.
- \$SUBROUTINES: Defines any advanced mathematical models (e.g., Michaelis-Menten kinetics) you might be using.
- 5. **\$MODEL:** Defines the structural PK model (compartments, how drug moves between them).
- \$PK: Describes the pharmacokinetic parameters you want to estimate (e.g., clearance (CL), volume of distribution (V), absorption rate constant (KA)).
- 7. \$ERROR: Defines your residual error model (how observed concentrations
 - deviate from the model's predictions) Errors in description of \$ESTIMATION
 - 8. **\$ESTIMATION:** Specifies the estimation method (e.g., FOCE) initial parametrization estimates, and requests for statistical outputs.
 - 9. **\$TABLE:** Controls the tables you want NONMEM to generate as output
 - Simple One-Compartment PK Example

Missing \$THETA, \$OMEGA, \$SIGMA

Code snippet		

: *** Example: One-Compartment PK Model *** \$PROBLEM One Compartment PK Model \$INPUT ID TIME DV AMT CMT EVID \$DATA mydata.csv IGNORE = @ missing \$SUBROUTINES ADVAN2 TRANS2 ; Model for a one nt PK profile \$MODEL CMT=1 ; Tell NONMEM we have Redundant code \$PK Missing scale factor S₂ = V ; Typical value of clearance Typical value of volume Absorption r Incorrect IIV, ETA \$PK TVCL = THETA(1) TVV = THETA(2) KA = THETA(3) Incorrect IIV, ETA : Inter-individual Variability (IIV) on parameters [ETA(1) = 0.2 ; IIV on CL (e.g., 20% coefficient of variation) ETA(2) = 0.1 ; IIV on V METHOD = 1 INTERACTION Incorrect description SERROR METHOD = I IN ICONCION Y = F*EXP(EPS(1)) ; Additive residual error model) \$ESTIMATION METHOD=FOCEI ; First-Order Conditional Estimation with Inte STABLE ID TIME DV IPRED DVRES CWRES Incorrect item name \$COVARIANCE PRINT=E IPRED not defined

Use code with caution.

Explanation of Key Sections

- SPROBLEM: A brief descriptor of the model.
- \$INPUT: Tells NONMEM how to read your data (column order)
 \$MODEL: Specifies that we have one compartment (CMT=1).
- \$PK:
- TVCL, TVV, KA are the typical values (think average) of your PK parameters to be estimated.
- ETA(1), ETA(2) represent inter-individual variability on clearance and volume.
- \$ERROR: An additive error model is used; observations (Y) are the model prediction (F) plus some error.
- **\$ESTIMATION:** The estimation method will be FOCE with interaction.

Important Notes:

- NONMEM uses its own syntax/formatting you'll need to study NONMEM documentation and examples to become proficient.
- This is a very basic model. Complexity will increase with multiple compartments, different dosing routes, covariates, more advanced error models, etc.

Let me know if you'd like to explore a more complex model (e.g., twocompartment, target-mediated drug disposition) or a specific aspect of NONMEM coding in more detail!

Gemini

Gemini provided the core structures of the NOMEM's NM-TRAN control records at the beginning and the code

for a simple one-compartment PK model. The structure of NONMEM code was listed in the expected order: problem statement (*\$PROBLEM*), data input (*\$INPUT*, *\$DATA*), model subroutine selection (*\$SUBROUTINE*),

_IO

PK parameters (PK), defining the residual error (ERROR) and outputting the results (TABLE). However, the simple one-compartment PK example provided was missing the crucial initial estimate code blocks: initial estimates for the OMEGA matrix (SOMEGA), initial estimates and bounds of fixed effects parameters (THETA), and initial estimates for the NONMEM SIGMA matrix (SSIGMA). Additionally, no inter-individual variability was specified in the PK block (i.e., the THETA values were not associated with a function that linked them to the inter-individual variability, e.g., *THETA*(1) * *exp*(*ETA*(1)) etc.

...

Case study 3. NONMEM coding

Case study 3A

Can you provide the NONMEM code for a linear PK model with oral administration?

Figure 3 summarizes the ChatGPT and Gemini results for Case Study 3A.

ChatGPT

ChatGPT

ChatGPT generated an instructive example of NONMEM code for a basic linear PK model with oral administration.

Gomini

Fig. 3 Results from ChatGPT (left) and Gemini (right) for the linear pharmacokinetic compartmental model with oral absorption (Case Study 3A). The ChatGPT and Gemini explanation of key components is cropped to improve readability of the figure. The errors and omissions in the code are highlighted in rectangles and described in the gold boxes

	Show drafts
ChatGPT	
Certainly! Below is an example of NONMEM code for a simple linear pharmacokinetic 💎 💎	Absolutely! Here's the NONMEM code for a linear, one-compartment PK model with
PK) model with oral administration. This type of model typically assumes first-order	oral administration, along with explanations:
orption and elimination processes. Here's a basic structure for such a model:	
xt 🖸 Copy code	Code snippet
	; *** One-Compartment Model, Oral Administration ***
c Linear PK model with Oral Administration	\$PROBLEM One Compartment PK with Oral Dosing
csv IGNORE=C	\$INPUT ID TIME DV AMT CMT EVID
	\$DATA mydata.csv
TIME AMT DV	
INES ADVAN2 TRANS2	\$SUBROUTINES ADVAN2 TRANS2 ; One-compartment model specification
	\$MODEL CMT=1 ; Central compartment Redundant code
Missing scale factor S2 = V	SPK Incorrect parameter names
definitions 1) ; Absorption rat 🕕 nstant	TVCL = THETA(1) * EXP(ETA(1)); Typical clearance (L/h) TVW = THETA(2) * EXP(ETA(2)); Typical volume of distribution (L) KA = THETA(3); Absorption rate constant (1/h)
A(1) ; Absorption rat histant A(2) ; Clearance	METHOD & INTEDACTION
TA(3) ; Volume of distribution	<pre>\$ERROR Y = F + EPS(1) ; \$imple additive error model</pre>
Diculation of concentration Wrong description of K = CL/V	
CL/V ; Elimination rate constant	\$ESTIMATION METHOD=FOCEI SIG=0.2 ; Estimation with interaction, Initian STABLE ID TIME DV IPRED DVRES CWRES SIG is incorrect
Conflicting residual error model	IPRED, DVRES not defined
F ; Individual predicted concentration DV - IPRED; Individual residuals	Missing \$THETA, \$OMEGA, \$SIGMA
= DV - IPRED; INGIVIDUAL RESIDUALS SQRT(IPRED) ; Weighting for residual error	
PRED + W*EPS(1) ; Observed concentration with error	
Initial estimate for KA	
Initial estimate for KA Solutial estimate for CL Solution Fixed initial estimate for an ETA that is not used	
(); Initial estimate for V	
GA ; Random inter-individual variability on parameters	
IIV not specified	
SIGRA	
; Proportional error	
TIMATION METHOD=FOCE INTERACTION Incorrect method	
COVARIANCE METHOD = 1 INTERACTION	
OVARIANCE METHOD = 1 INTERACTION	
SCOVARIANCE METHOD = 1 INTERACTION STABLE ID TIME PRED DV IPRED IRES RES W	
SCOVARLANCE METHOD = 1 INTERACTION \$TABLE ID TIME PRED DV IPRED IRES RES W Explanation of Key Components:	
SCOURTAINCE METHOD = 1 INTERACTION \$TABLE 1D TIME PRED DV TIRED TRES RES W W xplanation of Key Components: \$PR00 ": Describes the problem, here a basic linear PK model for oral administration.	
SCOVARIANCE STABLE 10 TIME FRED BY IPRED TRES RES IN planation of Key Components: SPROB : Describes the problem, here a basic linear PK model for oral administration. SDATA : Specifies the dataset file and the option to ignore certain records (e.g.,	
METHOD = 1 INTERACTION ABLE 10 TIME PRED BV IPRED IRES RES W anation of Key Components: Ros : Describes the problem, here a basic linear PK model for oral administration. ATA : Specifies the dataset file and the option to ignore certain records (e.g., nmented lines).	
OWNERANCE METHOD = 1 INTERACTION ABLE TO TIVE PRED BY IPRED TRES RES W anation of Key Components: R00 ": Describes the problem, here a basic linear PK model for oral administration. ATA: Specifies the dataset file and the option to ignore certain records (e.g., mented lines). wmented lines). WT: Defines the columns in the dataset, including 'ID' (subject identifier),	
VARCHARGE METHOD = 1 INTERACTION BLE TO TIME PRED BY TERED TIRES RES IN halion of Key Components: DB ': Describes the problem, here a basic linear PK model for oral administration. TA ': Specifies the dataset file and the option to ignore certain records (e.g., mented lines). PUT ': Defines the columns in the dataset, including 'TD' (subject identifier), E' (time of observation), 'ANT' (amount of drug administered), and 'DV'	
OWARTANCE METHOD = 1 INTERACTION ABLE 10 TIME PRED DV IFRED IRES RES W INTERACTION anation of Key Components: INTERACTION ROB :: Describes the problem, here a basic linear PK model for oral administration. Arta :: Specifies the dataset file and the option to ignore certain records (e.g., mmented lines). NPUT :: Defines the columns in the dataset, including 'ID' (subject identifier), EV (time of observation). 'Art' (amount of drug administered), and 'DV' served drug concentration).	
CONCERNICE METHOD = 1 INTERACTION TABLE 10 TIME PRED by IPRED TABLES RES IF Image: Interaction of Key Components: Namation of Key Components: Image: Interaction of Key Components: PROB :: Describes the problem, here a basic linear PK model for oral administration. DATA :: Specifies the dataset file and the option to ignore certain records (e.g., mmented lines). INTEW: (Image of observation), AMT : (amount of drug administered), and 'DV' Descrived true poncentration). SUBROUTINES :: Specifies the subroutine used for the model. 'ADVAR2' and	
Describes METHOD = 1 INTERACTION ARALE 10 TIME PRED BV IPRED TRES RES IF anation of Key Components: PROB : Describes the problem, here a basic linear PK model for oral administration. ATA : Specifies the dataset file and the option to ignore certain records (e.g., mmented lines). PMUF : Defines the columns in the dataset, including 'ID' (subject identifier), Specifies the columns in the dataset, including 'ID' (subject identifier), Specifies the solution). Specifies the columns in the dataset, including 'ID' (subject identifier), Specifies the solution). Specifies the columns in the dataset, including 'ID' (subject identifier), Specifies the solution. Specifies the columns in the dataset, including 'ID' (subject identifier), Specifies the subroutine used for the model. 'ADVAR2' and DATASE: 'Specifies the subroutine used for the model.' ADVAR2' and	
OWDERANCE METHOD = 1 INTERACTION ABLE 10 TIME PRED 0V IPRED TRES RES W Ination of Key Components: ROB: Describes the problem, here a basic linear PK model for oral administration. Anata is specifies the dataset file and the option to ignore certain records (e.g., mmented lines). NPUT : Defines the columns in the dataset, including 'ID' (subject identifier), WE' (time of observation), 'AT' (amount of drug administered), and 'DV' served drug concentration). VBROUTINES 'Specifies the subroutine used for the model. 'ADVAR2' and AMS2' are appropriate for a one-compartment model with first-order absorption	
METHOD = 1 INTERACTION SEE TO TIME FRED BY TREED IF SEE ST Hation of Key Components: SE : Describes the problem, here a basic linear PK model for oral administration. Ar : Specifies the dataset file and the option to ignore certain records (e.g., nented lines). VIT : Defines the columns in the dataset, including 'ID' (subject identifier), C' (time of observation), 'AHT' (amount of drug administered), and 'DV' reved drug concentration). SegUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model. 'ADVAN2' and SEGUTIME : Specifies the subroutine used for the model with first-order absorption Jimination.	
Approximation METHOD = 1 INTERACTION LE 10 TIME PRED DY TREED TRES RES IT attion of Key Components: B': Describes the problem, here a basic linear PK model for oral administration. A': Specifies the dataset file and the option to ignore certain records (e.g., lented lines). U': Defines the columns in the dataset, including 'ID' (subject identifier), ''(time of observation), 'AMT' (amount of drug administered), and 'DV'' verd drug concentration). NORTINES 'Specifies the subroutine used for the model. 'ADVANZ ' and S22' are appropriate for a one-compartment model with first-order absorption imination. : Contains the parameter definitions and calculations for the model. Contains the enarmeter definitions and calculations for the model.	
ABEANCE METHOD = 1 INTERACTION LE 10 TIME PRED OV IFRED TRES RES IV ation of Key Components: B': Describes the problem, here a basic linear PK model for oral administration. A': Specifies the dataset file and the option to ignore certain records (e.g., ented lines). T': Defines the columns in the dataset, including 'ID' (subject identifier), ''(line of observation), 'ANT' (amount of drug administered), and 'DV' ved drug concentration). ROUTINES ''Specifies the subroutine used for the model. 'ADVAN2' and S2' are appropriate for a one-compartment model with first-order absorption mination. Contains the parameter definitions and calculations for the model. M': Describes initial estimates for the parameters: absorption rate constant (KA),	
CONSERVACE METHOD = 1 INTERACTION ABLE 10 TINE PRED BY IFRED TRES RES IF INTERACTION ABLE 10 TINE PRED BY IFRED TRES RES IF INTERACTION ADL 10 TINE PRED BY IFRED TRES RES IF INTERACTION ATA: Specifies the problem, here a basic linear PK model for oral administration. ATA: Specifies the dataset line and the option to ignore certain records (e.g., moneted lines). NPUT: Defines the columns in the dataset, including "ID" (subject identifier), Served drug concentration). NPUT: Defines the columns in the dataset, including "ID" (subject identifier), Served drug concentration). UBROUTINES 'Specifies the subroutine used for the model. 'ADVARA' and AIAS2' are appropriate for a one-compartment model with first-order absorption leimination. K': Contains the parameter definitions and calculations for the model. K': Contains the error model. This example uses a proportional error model. META': Provides initial estimates for the parameters: absorption rate constant (KA), trance(CL), and volume of distribution (V). Contains the constant (KA), trance(CL), and volume of distribution (V).	
METHOD = 1INTERACTION LE 10 TIME PRED DV IFRED TOES RES W withon of Key Components: **: Describes the problem, here a basic linear PK model for oral administration. **: Specifies the dataset file and the option to ignore certain records (e.g., ented lines). **: Defines the columns in the dataset, including '10' (subject identifier), (time of observation), AUT 'amount of drug administered), and '19' we drug concentration). **: The drug of the dataset including '10' (subject identifier), (time of observation), AUT 'amount of furg administered), and '19' we drug concentration). **: Specifies the subroutine used for the model. 'ADVMR2' and **: appropriate for a one-compartment model with first-order absorption mination. Contains the parameter definitions and calculations for the model. **: Provides initial estimates for the parameters: absorption rate constant (KA), the 'Specifies the residual unexplained variability: **: Specifies the residual unexplained variability. **: Defines the residual unexplained variability. **: Defines the residual unexplained variability (RUV).	
DETANCE METHOD = 1 INTERACTION LE 10 TIME PRED by IRRED TREES RES IN Status Describes the problem, here a basic linear PK model for oral administration. Status Status S	
METHOD = 1 INTERACTION SUB TO TWE FRED BY TREED THES RES T Antion of Key Components: De : Describes the problem, here a basic linear PK model for oral administration. At : Specifies the dataset file and the option to ignore certain records (e.g., nented lines). UP : Defines the columns in the dataset, including 'ID' (subject identifier), E' (time of observation), 'AH' (amount of drug administered), and 'DV' rived drug concentration). EV : Defines the columns in the dataset, including 'ID' (subject identifier), E' (time of observation), 'AH' (amount of drug administered), and 'DV' rived drug concentration). EV : Defines the erain of the model 'ADVAR2' and ES2' are appropriate for a one-compartment model with first-order absorption iminiation. : Contains the parameter definitions and calculations for the model. EX3 : Poscribes the error model. This example uses a proportional error model. EX4 : Specifies the random inter-individual variability. MA: Defines the residual unexplained variability (RUV). INATON: Indicates the method for parameter subsorption rate constant (KA), and (CL), and volume of distribution (V). EX4 : Specifies the random inter-individual variability. HAX: Defines the residual unexplained varia	
METHOD = 1 INTERACTION REF TO TIVE FRED IV FRED ICES RES IV Mation of Key Components: DP : Describes the problem, here a basic linear PK model for oral administration. A: Specifies the dataset file and the option to ignore certain records (eg., mented lines). UT : Defines the columns in the dataset, including 'TD' (subject identifier), E: (time of observation), 'MT' (amount of drug administrated), and 'DV' road drug concentration). NROUTINES: Specifies the subroutine used for the model. 'ADVARD' and SE2' are appropriate for a one-compartment model with first-order absorption minimation. :: Contains the parameter definitions and calculations for the model. KOR 'Describes the error model. This example uses a proportion aleror model. TA: 'Specifies the submodine used for the parameter: absorption aleror model. SE4': Describes the error model. This example uses a proportion aleror model. SE4': Specifies the submodine (V). SE4': Specifies the residual unexplained variability. MA: 'Defines the residual unexplained variability (RVV). TURATEN: 'Indicates the method for parameter estimation, here the First Order titional Estimation with Interaction (FOCE INTERACTION). MATANEE: C. Requests a covariance step.	
Description Description RATE LIG TIME PRED BY IFRED INES RES IN	
CONCREASE METHOD = 1 INTERACTION ARGLE 10 TIME PRED by IMPED IRES RES IF anation of Key Components: RADE 50 TIME PRED by IMPED IRES RES IF RADE 50 Excilies the problem, here a basic linear PK model for oral administration. ATA : Specifies the dataset file and the option to ignore certain records (e.g., mmented lines). MPUT : Defines the columns in the dataset, including 'ID' (subject identifier), the '(ime of observation). MEY : Defines the columns in the dataset, including 'ID' (subject identifier), the '(ime of observation). MEY : Defines the columns in the dataset, including 'ID' (subject identifier), the '(ime of observation). MEWOTITHE: 'Specifies the subroutine used for the model. 'AdvANZ' and 'Advector' appropriate for a one-compartment model with first-order absorption alertor model. MERT : Provides initial estimates for the parameters absorption rate constant (KA), arance (CL), and volume of distribution (V). MERA : 'Specifies the readom inter-individual variability. MERA : 'Specifies the readom inter-individual variability. META : Torvides initial estimated for parameter estimation, here the First Order andional Estimation with Interaction (FOCE INTERACTION). MERA : 'Specifies the output to be generated.	
METHOD = 1 INTERACTION BLE ID TIME FRED by 19:ED INES RES W Anation of Key Components: DB : Describes the problem, here a basic linear PK model for oral administration. TA : Specifies the dataset line and the option to ignore certain records (e.g., mented lines). PUT : Defines the columns in the dataset, including 'ID' (subject identifier), E' (time of observation), 'AIT' (amount of drug administered), and 'DV' evend drug concentration. BROUTINES : Specifies the subroutine used for the model. 'ADVANZ ' and MSZ' are appropriate for a one-compartment model with first-order absorption elimination. ': Contains the parameter definitions and calculations for the model. RROUTINES : Specifies the error model. This example uses a proportional error model. ETA : Provides initial estimates for the parameters: absorption rate constant (KA), rance (CL), and volume of distribution (V). ETA : Towides initial estimates for the variability. ETA: : Defines the random inter-individual variability. ETA: : Defines the random inter-individual variability. ETA: : Defines the method for parameter estimation, here the First Order ditional Estimation with interaction (POCE INTERACTION). VARENCE: : Requests a covariance step. BLE : Specifies the output to be generated. Erds is a basic starting point and might need adjustments based on the specific	
WARTAGE METHOD = 1 INTERACTION BILE TO TUPE PRED OV 199ED IGES RES VI	
METHOD = 1 INTERACTION TABLE ID TIME PRED BY IPRED IPRES RES W Ianation of Key Components: PROB : Describes the problem, here a basic linear PK model for oral administration.	
METHOD = 1 INTERACTION BLE TO TIME FRED BY TREED IN EAST OF THE ACTION BLE TO TIME FRED BY TREED IN EAST OF THE ACTION AND AND AND AND AND AND AND AND AND AND	

The response begins with the *\$PROB* statement, effectively setting the context as a basic linear PK model for oral drug administration. The inclusion of *\$DATA* and *\$INPUT* sections, specifying the datafile and defining essential data columns like *ID*, *TIME*, *AMT*, and *DV*.

In the \$*SUBROUTINES* section, ChatGPT appropriately selected *ADVAN2* and *TRANS2*, suitable for a one-compartment model with first-order absorption and elimination. The \$*PK* section, which is used to model the values of basic and additional PK parameters, was well-constructed, with clear definitions for the absorption rate constant (*KA*), clearance (*CL*), and volume of distribution (*V*), along with the calculation for the elimination rate constant (*K*).

ChatGPT's choice of the first order conditional estimation with interaction (FOCE INTERACTION) method in the *\$ESTIMATION* section, and the request for covariance analysis (*\$COVARIANCE*) and output specifications (*\$TABLE*), demonstrates an "understanding" of the modeling process in NONMEM.

The *\$ERROR* block incorrectly specified the residual error model. The formulas did not align with the standard additive or proportional error models and conflicted with the proportional error indicated in the *\$SIGMA* block. For a proportional error model, the correct equation is:

Y = IPRED + IPRED * EPS(1)

The LLM's choice of the FOCE INTERACTION method in the *\$ESTIMATION* section was problematic, leading to error messages upon running the code, necessitating a revision to METHOD = 1 or METHOD = COND. In the *\$TABLE*, previously calculated elimination rate constant was not included in the output.

Several revisions made to address the errors in the control stream before NONMEM would run without errors and warnings. These are presented sequentially for illustrative purposes in the Supplementary File.

Gemini

Gemini generated a NONMEM control stream for a onecompartment model with first-order absorption, which is also provided in Case 2 as an example of the NONMEM code. The response provided reasonable *\$PROBLEM* for the correct input item in *\$INPUT* section.

In the *\$SUBROUTINES*, Gemini appropriately selected *ADVAN2TRANS2* for one-compartment model with first order absorption. However, it also generated the *\$MODEL* that cannot be used in the selected subroutine. This redundant code block will cause errors when running the model in NONMEM.

Gemini correctly selected CL, V, and KA as the PK parameters in PK, and included exponential BSV on CL

and V. However, incorrect parameter names (*TVCL* and *TVV*) were used. In addition, the scaling factor S2 = V is missing in PK.

The *\$ESTIMATION* block is problematic as Gemini used METHOD = FOCEI to specify FOCEI method, which should be coded as METHOD = 1 *INTERACTION* or METHOD = COND *INTERACTION*. Gemini also chose an inappropriate term and value for number of significant digits using SIG = 0.2 instead of an integer value for *NSIG*. Significant digits are specified when using the differential equation subroutines (where a solution tolerance is specified), not when using the algebraic solutions for simple PK models in PREDPP.

As for the output table, Gemini included *IPRED* and *DVRES*, which were not defined in the previous section. More importantly, Gemini missed *\$THETA*, *\$OMEGA*, and *\$SIGMA* in the control stream, leaving the control stream incomplete. This error also occurred in Case 2.

Case study 3B

Provide NONMEM code for a one-compartment model with two parallel absorptions and linear elimination.

Figure 4 summarizes the ChatGPT and Gemini results for Case Study 3B.

ChatGPT

ChatGPT produced a NONMEM control stream for a onecompartment model with two parallel first order absorptions, which is a user-written model, that contained the correct code blocks. ChatGPT provided a correct *PROBLEM* code block and defined the key data items correctly in the dataset in *\$INPUT* block. However, in the *\$DATA* code block, Chat-GPT incorrectly included *IGNORE* = *CMT*(3).

In the \$SUBROUTINE section, ChatGPT inappropriately selected *ADVAN2* and *TRANS2*, which generated an error. For the control stream using differential equations, *ADVAN6*, *ADVAN8*, *ADVAN9* or *ADVAN13* should be selected, and a relative tolerance *TOL* needed to be specified.

In the *\$MODEL* section, ChatGPT correctly included two absorption depots and a central compartment. However, ChatGPT incorrectly defined the central compartment as the default dosing compartment.

In the PK section, ChatGPT correctly defined two first-order absorption rate constants (*KA*1 and *KA*2), clearance (*CL*), and volume of distribution (*V*) along with their between-subject variability (*BSV*). The ChatGPT code failed to distribute the dose into two different absorption pathways because a fraction parameter was not included in PK. The presence of redundant code regarding the *ETA* parameters also resulted in an error message. The *SDES* section had the correct ordinary differential equations for this model. Fig. 4 Results from ChatGPT (left) and Gemini (right) for a one-compartment model with two parallel absorption pathways and linear elimination (Case Study 3B). The Chat-GPT and Gemini explanation of key components is cropped to improve readability of the figure. The errors and omissions in the code are highlighted in rectangles and described in the gold boxes

ear Eliminati

	ChatGPT	Gemini		
P	You Provide the NONMEM code for a one compartment model with two parallel first-order absorptions and linear elimination.	Provide NONMEM code for a one-compartment model with two parallel absorptions and linear elimination.		
0	ChatGPT Creating a NONMEM (Nonlinear Mixed Effects Modeling) code for a pharmacokinetic model involves specifying the structural model, which in this case is a one-compartment model with two parallel first- order absorption processes and linear elimination. This model is useful for drugs administered via routes that lead to absorption through two parallel pathways, such as for all and sublingual, or for	Show drafts Absolutely! Here's a NONMEM code for the model you described, along with explanations: NONMEM Code		
1	formulations that result in two distinct absorption phases. Below is a simplified example of NONMEM code for this type of model. Please note that the actual implementation may vary depending on the specifics of your study, such as the parameterization of the model, the data belog analyzed, and any additional complexities like covariate models or inter- individual variability components you wish to include. The second study of the second st	Code snippet SPROBLEM One Comportment Model - Parallel Absorption - Linear Eliminat SIMPUT LD TIME DV AMT SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG TOL-5 ; 2 Depot compartments for parallel absorption SUBROUTINE ADVANG C = Clearance SW SUB = 0.5 ; Fraction in first absorption pathway SUB = 0.5 ; Fraction in first absorption pathway SUB = 0.5 ; Fraction in first absorption pathway SUB = 0.5 ; Fraction in first absorption pathway SUB = 0.5 ; Fraction in first absorption pathway SUB = 0.5 ; Fraction in first absorption pathway SUB = 0.5 ; Fraction in first absorption pathway SUB = 0.5 ; Fraction in first absorption pathway SUB = 0.5 ; Fraction in first absorption pathway		
	<pre>i befine actual parameters kW1 = TXW1 = ENV(= ENV(ETA(3)) KW2 = TXW2 = ENV(ETA(3)) SOES DADT(1) = -KA1*A(1) : Change in amount in DEPOT1 over time DADT(2) = -KA1*A(1) : KA1*A(2) - (CL/V)*A(3) : Change in amount in DEPOT2 over time DADT(3) = KA1*A(1) + KA2*A(2) - (CL/V)*A(3) : Change in amount in CENTRAL compartment SERROR IDMED = A(3)/V : Predicted concentration ITWE = ETA(1) W = SQRT(SIGMA(1)*2 + (SIGMA(2)*2)*IFRED*2) V = IDRED*(1+WFER(1)) : Observation model with proportional error STHETA (0,1) ; Guess for KA1 (0,2) ; Guess for KA1 (0,2) ; Guess for V SQMEGA 0.1 ; ITV block</pre>			
	SSTOMA 0.1 : Residual variability block \$5IGMA only includes a single initial estimate			

BLE ID TIME AMT DV PRED RES WRES ETA(1) ETA(2) ETA(3) ETA(4) ONEHEADER NOPRI

Certain error patterns identified in Case Study 3A persisted in Case Study 3B, e.g., the \$ERROR code block had incorrect standard deviation and proportional error model formulae. In addition, ChatGPT only provided a single initial estimate for the OMEGA matrix, and the code erroneously contained *METHOD* = *FOCE* to specify *FOCE* method instead of the correct METHOD = 1 or METHOD = COND.

The revisions made to address the errors and to obtain a NONMEM run without errors and warnings are summarized in the Supplementary File.

Gemini

Gemini provided a NONMEM control stream for a one-compartment model with parallel absorption and linear elimination. After generating a reasonable \$PROBLEM block, it correctly coded \$INPUT and \$DATA, with required input items.

Gemini correctly selected ADVAN6 as the subroutine, as this user-written model required differential equation solver. It also provided a reasonable value for the relative tolerance TOL. However, the \$MODEL generated by Gemini is problematic and should be revised to COMP = (DEPOT1) COMP = (DEPOT2) COMP = (CENT).

In *PK*, Gemini correctly defined all the required PK parameters in this PK model, including F1, F2, KA1, KA2, V, and CL. However, it provided an incorrect scale factor for the central compartment and did not specify any interindividual variability on the parameters.

The \$ERROR block incorrectly specified the residual error model. A correct \$EST was coded specifying FOCE method with interaction. Additionally, no initial estimates

were provided for the \$*OMEGA* matrix. It's worth noting that Gemini missed including \$*DES*, \$*THETA*, and \$*TABLE* in the control stream. These components are essential, and the model will not run without them.

Evaluation of reproducibility

The results from LLM can vary from one run to another for the same prompt. Three replicate experiments were conducted with ChatGPT and Gemini for Case Studies 3A and 3B.

ChatGPT

All three replicates contained errors and omissions. The results from the three replicate experiments for ChatGPT are summarized in Supplementary Figure S1 for Case Study 3A. In all three replicates: i) DES and MODEL were incorrectly included when using ADVAN2 and TRANS2, ii) the FOCE INTERACTION method in the SESTIMATION section was not properly coded as METHOD = 1 or METHOD = COND., and iii) either the IIV and/or error model definitions were incorrect. Two of the replicates did not have the correct S2 = V scaling factor. When included, all the MODEL and DES were either problematic or blank.

There were several errors unique to each replicate that occurred in different code blocks. Supplementary Figure S1 shows the corresponding replication experiments for Case Study 3A.

For Case Study 3B (Supplementary Figure S3), all three replicates contained the structural outline of the NONMEM control stream. However, in all three replicates, ChatGPT provided an initial estimate in \$OMEGA without including between-subject variability on any parameters in \$PK. The other errors were variable across the three trials (Supplementary Figure S3).

Gemini

For Case Study 3A, Gemini omitted \$DATA and \$SUB-ROUTINE in all replicates; \$THETA and \$ERROR were missed in two replicates. In all three replicates, \$MODEL and \$DES were problematic or blank. Two replicates contained incorrect comment statements (Supplementary Figure S2).

For Case Study 3B, two Gemini trials (Supplementary Figure S4) omitted important NM-TRAN control records such as \$PROBLEM, \$OMEGA, \$TABLE, \$DATA, and \$SUBROUTINE. All three replicates were missing CMT in \$INPUT. The second and third control streams used incorrect code in \$PK. There other errors are highlighted (Supplementary Figure S4).

Effect of varying "Temperature" hyperparameter

The results from experiments with "temperature" hyperparameter (T) values of 0.1, 0.33 and 1, using ChatGPT for Case Study 3A and Case Study 3B, are summarized in Supplementary Figure S5 and S6, respectively.

For Case Study 3A, the code from all three temperature settings contained redundant \$MODEL blocks and had incorrect scale factors in \$PK. The T = 0.1 and T = 0.33 code correctly included between subject variability on all three PK parameters, whereas the T = 1 code inappropriately fixed all the PK parameters in \$PK. The incorrect method name error wherein METHOD = FOCE was incorrectly used to specify the FOCE method, occurred only with T = 0.33.

For Case Study 3B, the T = 0.1 and T = 0.33 code inaccurately labeled default dose compartments. None of the trials correctly defined the fraction absorbed by the F1 and F2 pathways. The T = 1 code used atypical equations to define between subject variability on PK parameters that were found to be correct. Other common mistakes were also noted including incorrect method selection and conflicting IIV definitions.

Discussion

We evaluated ChatGPT and Gemini in several case studies that would enable us to delineate the strengths and limitations of using LLM for NONMEM coding, and to identify patterns in the coding errors that occurred. We focused on NONMEM because it is the most widely used coding framework in pharmacometrics. However, because most versions of NON-MEM are marketed commercially and not freely available to open-source software users [16], the volume of NONMEM code readily accessible online is modest compared to more widely used languages such as C + +, Python, and R. This makes NONMEM a challenging framework for LLMs, which depend on the availability of adequate training data.

The strength of ChatGPT and Gemini for NONMEM coding is that it can use the information from a short prompt provided by the user in lay language and provide a template of code containing the key components of a NONMEM control stream. The output from these LLMs is a good starting point for a coding project. The performance of ChatGPT and Gemini on the NONMEM coding tasks contained flaws and had focal structural (e.g., in Case Study 3B, the fraction of dose distributed between the parallel absorption compartments was not included) and NONMEM syntax (e.g., the FOCE method was incorrectly coded in both Case Study 3A and 3B) errors that require correction. We also found odd code snippets, e.g., NONMEM does not have \$*PARAM* code block. We were surprised at the overall quality of the syllabus outline

generated by ChatGPT and Gemini in Case Study 1, given that pharmacometrics is a niche sub-specialty in the pharmaceutical industry, and there are only a few academic institutions that conduct cutting-edge research projects or provide training with NONMEM [17].

Between run variability is an intrinsic feature in all LLM including ChatGPT and Gemini because the underlying algorithms are based on generative AI methodologies [7, 18]. We therefore conducted reproducibility experiments to gauge the extent of the variability. Although the structural outlines from the replicate runs for Case Study 3A and Case Study 3B were generally similar, each instance of code produced had different errors. A frequent error in the ChatGPT NONMEM code was incorrect assignment of *METHOD* = *FOCE*, which recurred in 8/12 prompts in the replication and temperature hyperparameter experiments,

The "temperature" hyperparameter T, which ranges from 0 to 1 (default value = 0.7), controls the balance between the deterministic and generative aspects of ChatGPT. A low T value setting of 0.1 increases the likelihood of more deterministic and consistent outputs whereas a high T value setting of 1 increases the likelihood that more "creative" outputs with greater generative randomness will be produced. Interestingly, the code from the high T = 1 setting for individual parameters in the PK block of Case Study 3B (Supplementary Figure S6) was atypical but correct. The temperature hyperparameter setting option was not publicly available in the Gemini Ultra 1.0 version that we used.

The code from both ChatGPTand Gemini are imperfect at generating NONMEM code. Shared errors patterns were seen across both LLMs, e.g., conflicting code blocks and selection of the incorrect method. However, each LLM had areas of strength and weakness. ChatGPT performed well in providing a structural outline of the control streams by providing required NM-TRAN control records that Gemini omitted (*\$SIGMA*, *\$OMEGA*, *\$THETA*). Gemini's code was more carefully fine-tuned, and in Case 3B, it contained the fractions of dose absorbed through the two parallel absorption pathways and correct removal of column names, which ChatGPT missed.

A weakness of our study is that we did not compare the NONMEM coding performance of ChatGPT to other LLM other than Gemini, e.g., Llama and Claude [1, 3, 5, 15]. We also did not examine ChatGPT and Gemini in the context of other software tools such as *mrgsolve* [19], *nlmxr* [20, 21], the Mixtran used by Monolix [22], and STAN [23] that might be used by pharmacometricians.

Comparatively, ChatGPT, Gemini, and other LLM are more proficient at generating code and it is projected that the adoption of LLM could yield significant productivity improvements for programmers. Cloesmeijer et al. found that ChatGPT can be used to obtain PK parameters from the literature, code a population model and generate visualizations in R [24]. However, Cloesmeijer et al. indicated that the performance of ChatGPT for NONMEM was poor but did not present research results [24]. In previous work, we found that R code generated with ChatGPT is of satisfactory quality [18]. The accuracy of ChatGPT in calculations involving exponential, logarithmic and trigonometric functions, which are common in pharmacometrics, is only ~ 50% [18, 25, 26]. Thus, conducting numerical PK and pharmacometrics calculations directly within the ChatGPT interface should be avoided for now. The citations generated by earlier versions of ChatGPT (e.g., ChatGPT 3.5) often contained errors that were referred to as "artificial hallucinations", but this issue has been substantially improved with the new algorithm [18, 27, 28]. Similarly, we expect that new enhancements to LLM will quickly mitigate the high frequency of error rates in numerical calculations.

In conclusion, our results show that the utility of Chat-GPT and Gemini for NONMEM coding might be metaphorically viewed as a cup that is currently half full. Although ChatGPT and Gemini may be useful for generating early versions of code, the resulting code requires careful review and changes before it can be run. However, LLMs are rapidly improving in their capabilities, and it might not be long before they are proficient at many NON-MEM coding tasks.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10928-024-09921-y.

Author contributions Euibeom Shin – Data analysis, manuscript preparation.

Yifan Yu - Data analysis, manuscript preparation.

Robert Bies – Manuscript preparation.

Murali Ramanathan – Study concept and design, data analysis, manuscript preparation.

Funding This is unfunded research. Support from Grant MS190096 from the Department of Defense Multiple Sclerosis Research Program for the Office of the Congressionally Directed Medical Research Programs (CDMRP) to the Ramanathan laboratory is gratefully acknowledged.

Declarations

Financial conflicts Dr. Bies receives grant funding from NIDA, NIAID, NICHD, USAID, Bill and Melinda Gates Foundation and serves as a consultant for Advanced Biosciences Laboratories (NIAID). In the past he has served as a consultant for Lumos Biopharma through NGT Biopharma Consultants. Dr. Murali Ramanathan received research funding from the National Multiple Sclerosis Society, Department of Defense, National Science Foundation, and National Institute of Neurological Diseases and Stroke. He receives royalty from a self-published textbook.

Competing interests The authors declare no competing interests.

References

- 1. ChatGPT Version Jan 2024 (2024) https://chat.openai.com/. Accessed Mar 2024
- Gemini Team, Anil R, Borgeaud S et al (2023) Gemini: A Family of Highly Capable Multimodal Models. arXiv:2312.11805. https://doi.org/10.48550/arXiv.2312.11805. Accessed Dec 01 2023. https://ui.adsabs.harvard.edu/abs/2023arXiv231211805G
- 3. Llama 2: open source, free for research and commercial use (2024) https://llama.meta.com/llama2/
- Touvron H, Martin L, Stone K, et al. Llama 2: Open Foundation and Fine-Tuned Chat Models. 2023: arXiv:2307.09288. https:// doi.org/10.48550/arXiv.2307.09288. Accessed Jul 01 2023. https://ui.adsabs.harvard.edu/abs/2023arXiv230709288T
- 5. Meet Claude (2024) https://www.anthropic.com/claude
- Orru G, Piarulli A, Conversano C, Gemignani A (2023) Humanlike problem-solving abilities in large language models using ChatGPT. Front Artif Intell 6:1199350. https://doi.org/10.3389/ frai.2023.1199350
- Roumeliotis KI, Tselikas ND (2023) ChatGPT and Open-AI Models: A Preliminary Review. Future Internet 15(6):192
- 8. Radford A, Narasimhan K, Salimans T, Sutskever I (2018) Improving language understanding by generative pre-training
- 9. Owen JS, Fiedler-Kelly J (2014) Introduction to population pharmacokinetic/pharmacodynamic analysis with nonlinear mixed effects models. Wiley
- Pétricoul O, Cosson V, Fuseau E, Marchand M (2007) Population models for drug absorption and enterohepatic recycling. Pharmacometrics: the science of quantitative pharmacology 345–382
- Bauer RJ (2019) NONMEM tutorial part I: description of commands and options, with simple examples of population analysis. CPT Pharmacometrics Syst Pharmacol 8(8):525–537. https://doi. org/10.1002/psp4.12404
- 12. Sun H, Fadiran EO, Jones CD et al (1999) Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 37:41–58
- 13 Cloesmeijer ME, Janssen A, Koopman SF, Cnossen MH, Mathôt RA, consortium S, (2024) ChatGPT in pharmacometrics? Potential opportunities and limitations. British J Clin Pharmacol 90(1):360–365
- Shin E, Ramanathan M (2024) Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model. J Pharmacokinet Pharmacodyn 51(2):101–108
- 15. Bard Large language model. 2023. https://bard.google.com
- Fidler M, Wilkins JJ, Hooijmaijers R et al (2019) Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages. CPT Pharmacometrics Syst Pharmacol 8(9):621–633. https://doi.org/10.1002/psp4.12445

- Bonate PL, Barrett JS, Ait-Oudhia S et al (2023) Training the next generation of pharmacometric modelers: a multisector perspective. J Pharmacokinet Pharmacodyn. https://doi.org/10.1007/ s10928-023-09878-4
- Shin E, Ramanathan M (2023) Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model. J Pharmacokinet Pharmacodyn. https://doi. org/10.1007/s10928-023-09892-6
- mrgsolve: Simulate from ODE-Based Models. R package version 1.4.1. Metrum Research Group; 2024. https://github.com/metru mresearchgroup/mrgsolve
- Fidler M, Hooijmaijers R, Schoemaker R, Wilkins JJ, Xiong Y, Wang W (2021) R and nlmixr as a gateway between statistics and pharmacometrics. CPT Pharmacometrics Syst Pharmacol 10(4):283–285. https://doi.org/10.1002/psp4.12618
- 21. nlmixr: an R package for population PKPD modeling. 2019. https://nlmixrdevelopment.github.io/nlmixr/index.html
- Anonymous. Monolix documentation. Lixoft-SimulationsPlus. Accessed March 13, 2024, 2024. https://monolix.lixoft.com/ single-page/
- Stan Reference Manual. NumFOCUS; 2011. https://mc-stan.org/ docs/reference-manual/
- Cloesmeijer ME, Janssen A, Koopman SF, Cnossen MH, Mathot RAA, Symphony consortium (2024) ChatGPT in pharmacometrics? Potential opportunities and limitations. Br J Clin Pharmacol 90(1):360–365. https://doi.org/10.1111/bcp.15895
- 25. Frieder S, Pinchetti L, Chevalier A et al (2023) Mathematical capabilities of ChatGPT. arXiv. arXiv:2301.13867v2
- Yuan Z, Yuan H, Tan C, Wang W, Huang S. How well do large language models perform in arithmetic tasks? arXiv. 2023:arXiv: 2304.02015
- Alkaissi H, McFarlane SI (2023) Artificial Hallucinations in ChatGPT: Implications in Scientific Writing. Cureus J Med Sci 15(2).https://doi.org/10.7759/cureus.35179
- 28 Beutel G, Geerits E, Kielstein JT (2023) Artificial hallucination: GPT on LSD? Crit Care 27(1):148. https://doi.org/10.1186/ s13054-023-04425-6

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.